{"id":56311,"date":"2024-06-18T00:05:26","date_gmt":"2024-06-18T00:05:26","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2024\/06\/18\/jasper-therapeutics-to-present-at-the-oppenheimer-novel-targets-in-immunology-summit\/"},"modified":"2024-06-18T00:05:26","modified_gmt":"2024-06-18T00:05:26","slug":"jasper-therapeutics-to-present-at-the-oppenheimer-novel-targets-in-immunology-summit","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/jasper-therapeutics-to-present-at-the-oppenheimer-novel-targets-in-immunology-summit\/","title":{"rendered":"Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit"},"content":{"rendered":"<div>\n<p align=\"justify\">REDWOOD CITY, Calif., June  17, 2024  (GLOBE NEWSWIRE) &#8212; Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced today announced that its management will present at the Oppenheimer Novel Targets in Immunology Summit, to be held on Monday, June 24, 2024, in New York City.<\/p>\n<p align=\"justify\"><strong>Oppenheimer Novel Targets in Immunology Summit <\/strong><br \/><strong>Presentation Date\/Time<\/strong>: Monday, June 24, 2024; 11:45 a.m. EDT<br \/><strong>Presentation<\/strong> <strong>Format<\/strong>: Panel Discussion \u2013 \u201cNovel Immunological Mechanisms for Dermatologic Disorders\u201d<\/p>\n<p align=\"justify\"><strong>About Jasper<br \/><\/strong>Jasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast and stem cell diseases such as chronic urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) and as a conditioning agent for stem cell transplants for rare diseases such as sickle cell disease (SCD), Fanconi anemia (FA) and severe combined immunodeficiency (SCID). To date, briquilimab has a demonstrated efficacy and safety profile in more than 145 dosed participants and healthy volunteers, with clinical outcomes as a conditioning agent in SCID, acute myeloid leukemia, MDS, FA, and SCD. For more information, please visit us at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9ORA2KfcrmIisj8t90NO0H4oj_WIWAeaqcteNcFD2B-oSd8LjpUWYdealwRLtR8CRiY1rjf38rC1u5yYETeXWZ2IYAmN1A1yPhlFXHV8iHU2N2VdpgF4jEdeFmhoqrb2pIJ9_pfnjOCClNwCEYvBtRNHEGzU_rquPtOVSzGM_Paw7T0-5usjZ15BmXao5uP_rq8qZyutf-AOv-Ima80Fg9JAPUA0N5DMLfXgE_aDS44dJNMn2Zp_0gZxADiPuSk92WwI5zF1S1Kk9Tt12W4w0WT3O_ga9ZKTwDFfwgDZ0X4=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"www.jaspertherapeutics.com\">www.jaspertherapeutics.com<\/a>.<\/p>\n<p align=\"justify\"><strong>Forward-Looking Statements<br \/><\/strong>Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as \u201cbelieve,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cestimate,\u201d \u201ccontinue,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cexpect,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201cplan,\u201d \u201cpredict,\u201d \u201cpotential,\u201d \u201cseem,\u201d \u201cseek,\u201d \u201cfuture,\u201d \u201coutlook\u201d and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Jasper\u2019s presentation at the Oppenheimer Novel Targets in Immunology Summit, and briquilimab\u2019s potential to address mast cell driven diseases such as CSU, CIndU and asthma. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jasper\u2019s product candidates may not be beneficial to patients or successfully commercialized; patients\u2019 willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper\u2019s business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper\u2019s business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jasper\u2019s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or Jasper\u2019s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jasper\u2019s assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.<\/p>\n<p align=\"justify\"><strong>Contacts:<\/strong><\/p>\n<p>Joyce Allaire (investors)<br \/>LifeSci Advisors<br \/>617-435-6602<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=P0-KCKypRJEaua7RaTYkvFXhU6Wxd9gWY_vYzaU4qddi1zkYXIzAN7-P5ODfYggr02X0ItfbQmnFdsVMCTViZP0-FpqakRqojK-TMb3HDZFQ9u-Fsky9caS-jM1QCgXo\" rel=\"nofollow noopener\" target=\"_blank\" title=\"jallaire@lifesciadvisors.com\">jallaire@lifesciadvisors.com<\/a><\/p>\n<p>Alex Gray (investors)<br \/>Jasper Therapeutics<br \/>650-549-1454 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hYRPrw4MJ5OJiOnMeonbj7lTaOrnEFHKfQq5ZYdnIVmL831-hN8N7ECJ2DxEe57NLHa58FVKlr6sLmib9varIwa9dPEUYeZMXMdsEeEjiyOkLTMU8JGP_NB10BvZ_RMG\" rel=\"nofollow noopener\" target=\"_blank\" title=\"agray@jaspertherapeutics.com\">agray@jaspertherapeutics.com<\/a><\/p>\n<p>Lauren Walker (media)<br \/>Real Chemistry<br \/>646-564-2156<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pvLVWuZFKjC9vYfZLUKBQPZYy7Ix1rvOGDpe1p8GEAG3DcLTBkT68pw4klG7jH1meeGL8ezEw2oyjmrlRTdnq13KwZDaRWP96VwU5oOaOyyuLNkZqDdSJsc8JvXEZIsQ\" rel=\"nofollow noopener\" target=\"_blank\" title=\"lbarbiero@realchemistry.com\">lbarbiero@realchemistry.com<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YjNlNmRlOWYtYzY4Yy00NmVhLWFmZmQtZmRiNTMzOGIzYWY5LTEyMjIwNDc=\/tiny\/Jasper-Therapeutics-Inc-.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>REDWOOD CITY, Calif., June 17, 2024 (GLOBE NEWSWIRE) &#8212; Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced today announced that its management [&#8230;]\n","protected":false},"author":1,"featured_media":85254,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-56311","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/jasper-therapeutics-to-present-at-the-oppenheimer-novel-targets-in-immunology-summit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit\" \/>\n<meta property=\"og:description\" content=\"REDWOOD CITY, Calif., June 17, 2024 (GLOBE NEWSWIRE) &#8212; Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on dev\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/jasper-therapeutics-to-present-at-the-oppenheimer-novel-targets-in-immunology-summit\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2024-06-18T00:05:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/06\/Jasper-Therapeutics-Inc-1-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/jasper-therapeutics-to-present-at-the-oppenheimer-novel-targets-in-immunology-summit\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/jasper-therapeutics-to-present-at-the-oppenheimer-novel-targets-in-immunology-summit\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit\",\"datePublished\":\"2024-06-18T00:05:26+00:00\",\"dateModified\":\"2024-06-18T00:05:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/jasper-therapeutics-to-present-at-the-oppenheimer-novel-targets-in-immunology-summit\/\"},\"wordCount\":775,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/jasper-therapeutics-to-present-at-the-oppenheimer-novel-targets-in-immunology-summit\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/jasper-therapeutics-to-present-at-the-oppenheimer-novel-targets-in-immunology-summit\/\",\"name\":\"Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2024-06-18T00:05:26+00:00\",\"dateModified\":\"2024-06-18T00:05:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/jasper-therapeutics-to-present-at-the-oppenheimer-novel-targets-in-immunology-summit\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/jasper-therapeutics-to-present-at-the-oppenheimer-novel-targets-in-immunology-summit\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/jasper-therapeutics-to-present-at-the-oppenheimer-novel-targets-in-immunology-summit\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/jasper-therapeutics-to-present-at-the-oppenheimer-novel-targets-in-immunology-summit\/","og_locale":"en_US","og_type":"article","og_title":"Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit","og_description":"REDWOOD CITY, Calif., June 17, 2024 (GLOBE NEWSWIRE) &#8212; Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on dev","og_url":"https:\/\/english.saigonbiz.com\/vn\/jasper-therapeutics-to-present-at-the-oppenheimer-novel-targets-in-immunology-summit\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2024-06-18T00:05:26+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/06\/Jasper-Therapeutics-Inc-1-1.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/jasper-therapeutics-to-present-at-the-oppenheimer-novel-targets-in-immunology-summit\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/jasper-therapeutics-to-present-at-the-oppenheimer-novel-targets-in-immunology-summit\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit","datePublished":"2024-06-18T00:05:26+00:00","dateModified":"2024-06-18T00:05:26+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/jasper-therapeutics-to-present-at-the-oppenheimer-novel-targets-in-immunology-summit\/"},"wordCount":775,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/jasper-therapeutics-to-present-at-the-oppenheimer-novel-targets-in-immunology-summit\/","url":"https:\/\/english.saigonbiz.com\/vn\/jasper-therapeutics-to-present-at-the-oppenheimer-novel-targets-in-immunology-summit\/","name":"Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2024-06-18T00:05:26+00:00","dateModified":"2024-06-18T00:05:26+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/jasper-therapeutics-to-present-at-the-oppenheimer-novel-targets-in-immunology-summit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/jasper-therapeutics-to-present-at-the-oppenheimer-novel-targets-in-immunology-summit\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/jasper-therapeutics-to-present-at-the-oppenheimer-novel-targets-in-immunology-summit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/56311","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=56311"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/56311\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/85254"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=56311"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=56311"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=56311"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}